Elizabeth Thomas, DO
Rheumatology · Wilmington, NCNPI 1366867269
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Amgen at 32.1% of the total. That places this record below the midpoint for rheumatology clinicians in NC, where the typical reported total is $3,350.
Across 22 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$126
- AbbVie$103
- Novartis$70
- Fresenius Kabi USA, LLC$20
- Actelion Pharmaceuticals US, Inc.$16
- Aurinia Pharma U.S., Inc.$15
- plus $42 from 3 others
What the payments were for
- Food & beverage$393100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $126 |
| AbbVie | 7 | $103 |
| Novartis | 5 | $70 |
| Fresenius Kabi USA, LLC | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Aurinia Pharma U.S., Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
How this compares
$393 in reported general payments places this provider in the 20th percentile of 210 rheumatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 54 | $1,929 |
| MethotrexateMethotrexate Sodium | 62 | $1,420 |
| Gabapentin | 104 | $1,190 |
| Colchicine | 20 | $633 |
| Prednisone | 71 | $561 |
| Allopurinol | 39 | $478 |
| Duloxetine Hcl | 23 | $334 |
| Methylprednisolone | 30 | $208 |
| Alendronate Sodium | 33 | $203 |
| Pregabalin | 11 | $176 |
| Cyclobenzaprine Hcl | 23 | $174 |
| Tramadol Hcl | 43 | $131 |
| Meloxicam | 19 | $117 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Wilmington
- Wendy SimmonsWilmington$462K
- Mark HarrisWilmington$22K
- Ronald GeorgeWilmington$19K
- Heather FavoritoWilmington$9K
- Gordon LamCharlotte$2.7M
- Ralph SnydermanDurham$1.3M
- Andrew LasterCharlotte$421K
- Ana RossRaleigh$417K
- Gwenesta MeltonFayetteville$410K
- Joseph ShanahanDurham$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.